Atossa Therapeutics Passes Five-Year Reauthorization Of Rare Pediatric Disease Priority Review Voucher Program

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today reaffirmed its strong market position around its Duchenne Muscular Dystrophy (DMD) program following  yesterday's congressional announcement that it had passed a five-year reauthorization of the Rare Pediatric Disease Priority Review Voucher ("PRV") Program. The program extends the Company's ability to be eligible to receive a future PRV upon the U.S. Food and Drug Administration's ("FDA") approval following the FDA granting Rare Pediatric Disease ("RPD") designation to (Z)-endoxifen for the treatment of DMD late last year.